Sprint Bioscience AB (publ) (STO:SPRINT)
Sweden
· Delayed Price · Currency is SEK 0.4240
0.00 (0.00%)
May 21, 2025, 9:00 AM CET
Sprint Bioscience AB Revenue
In the year 2024, Sprint Bioscience AB had annual revenue of 66.14M SEK with 27.97% growth. Sprint Bioscience AB had revenue of 16.77M in the quarter ending December 31, 2024, with 38.82% growth.
Revenue
66.14M
Revenue Growth
+27.97%
P/S Ratio
0.68
Revenue / Employee
1.74M
Employees
38
Market Cap
44.74M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 66.14M | 14.46M | 27.97% |
| Dec 31, 2023 | 51.69M | 51.60M | 62,171.08% |
| Dec 31, 2022 | 83.00K | -34.95M | -99.76% |
| Dec 31, 2021 | 35.03M | 15.83M | 82.49% |
| Dec 31, 2020 | 19.20M | -14.62M | -43.23% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Swedish Orphan Biovitrum AB | 26.24B |
| Sectra AB | 3.30B |
| Getinge AB | 35.57B |
| Medicover AB | 23.56B |
| Camurus AB | 2.04B |
| AddLife AB | 10.42B |
| Vitrolife AB | 3.61B |
| Vimian Group AB | 4.24B |